The IPECAD Alzheimer’s disease model (Green et al, 2019) has been developed by the IPECAD Modelling Group as a framework to model disease progression across Alzheimer’s disease (AD) and to assess the costs and outcomes associated with the condition, and the cost-effectiveness of interventions for people affected by AD, using the scenario of a future disease modifying therapies (DMT) for people with mild cognitive impairment (MCI) due to AD.
A description of the model (version 1.0) is published open-access in the journal Alzheimer’s and Dementia: the journal of the Alzheimer’s Association. DOI:doi1234567890. LINK
You can use this open-source model for free under the Creative Commons Attribution-ShareAlike 4.0 International Public License.
We host a version history developed by the IPECAD Modelling Group below.
We provide a listing of self-reported external applications of the model below to endorse transparency.
Request a download link
External applications & involvements
2020 October: Bengt Winblad has provided general advise for Grifols International – AMBAR commercial Development who have requested the IPECAD model version 1.0.
2020 May-August: Ron Handels has guided two master students who have applied the IPECAD model version 1.0 in their internship (Health, Policy and Management master’s program at Maastricht University).
Anders Gustavsson (Karolinska Institutet, Sweden)
Colin Green (University of Exeter, UK)
Ron Handels (Karolinska Institutet, Sweden; Maastricht University, Netherlands)
Linus Jönsson (Karolinska Institutet, Sweden)
Andreas Karlson (Karolinska Institutet, Sweden)
Anders Sköldunger (Karolinska Institutet, Sweden)
Anders Wimo (Karolinska Institutet, Sweden)
Bengt Winblad (Karolinska Institutet, Sweden)